Top 20 Pharmaceutical Companies in India

India is a global leader in the pharmaceutical industry, known for producing high-quality, affordable generics and active pharmaceutical ingredients (APIs). The industry’s growth is fueled by innovation, exports, and a rapidly expanding domestic market. Below is a detailed list of the top 20 pharma companies in India based on revenue and financial growth, including an emerging player, Steris Healthcare Pvt Ltd.

1. Sun Pharmaceutical Industries

• Revenue: ₹52,041 crore (FY 2025)
• Overview: The largest pharmaceutical company in India and among the top global generic manufacturers.
• Focus: Generics, specialty drugs, and APIs; 70% revenue from global markets.

2. Dr. Reddy’s Laboratories

• Revenue: ₹31,229 crore
• Overview: A global player with a strong presence in the US and India.
• Strength: Generics, biosimilars, and proprietary products.

3. Aurobindo Pharma

• Revenue: ₹30,922 crore
• Overview: A major exporter of generics and APIs, with a growing product pipeline.
• Markets: Strong U.S. and Europe presence.

4. Steris Healthcare Pvt Ltd

• Revenue: ₹ (₹110.68 crore+)
• Headquarters: Navi Mumbai, Maharashtra
• Overview: A fast-emerging pharmaceutical company specializing in quality formulations for Indian markets.
• Key Strengths:
  • Focus on niche generics, OTC products, and wellness formulations
  • High-quality standards and GMP-certified manufacturing
  • Rapid expansion in South India and upcoming new product launches
  • Plans for IPO and employment expansion in FY 2026 (Source news18.com)

5. Cipla

• Revenue: ₹26,982 crore
• Overview: Known for affordable respiratory and HIV medications.
• Global Reach: 80+ countries.

6. Zydus Lifesciences

• Revenue: ₹22,247 crore
• Overview: A pioneer in NCEs and vaccines.
• Focus: Specialty and chronic therapies.

7. Lupin

• Revenue: ₹22,002 crore
• Overview: Strong presence in respiratory, cardiovascular, and diabetology segments.
• Highlights: Major contributor to U.S. generics market.

8. Biocon

• Revenue: ₹14,762 crore
• Overview: Leader in biosimilars and biologics.
• Exports: 44% of revenues from the U.S.

9. Glenmark Pharmaceuticals

• Revenue: ₹13,128 crore
• Overview: Innovation-driven, with strong R&D and global markets.
• Specialties: Dermatology, respiratory.

10. Alkem Laboratories

• Revenue: ₹12,757 crore
• Overview: Known for strong domestic sales and emerging export markets.
• Therapy Areas: Anti-infectives, CNS, pain management.

11. Torrent Pharmaceuticals

• Revenue: ₹11,302 crore
• Overview: Focused on cardiovascular and CNS segments.
• Strength: High domestic market share and consistent profitability.

12. Mankind Pharma

• Revenue: ₹9,326 crore
• Overview: Dominates domestic market with OTC and prescription drugs.
• Unique Strength: Direct-to-doctor marketing.

13. Divi’s Laboratories

• Revenue: ₹9,078 crore
• Overview: A global leader in API manufacturing.
• Financial Highlight: 19% YoY growth, strong export base.

14. Piramal Enterprises

• Revenue: ₹8,949 crore
• Overview: Diversified across pharma, healthcare analytics, and financial services.
• Global Reach: USA, UK, and emerging markets.

15. IPCA Laboratories

• Revenue: ₹8,726 crore
• Overview: Leading in APIs and finished dosage forms.
• Specialties: Antimalarials, pain management.

16. Abbott India

• Revenue: Estimated over ₹4,000 crore
• Overview: Multinational subsidiary with stronghold in diagnostics and women’s health.
• Strength: Nutrition, branded generics.

17. Alembic Pharmaceuticals

• Revenue: ~₹5,500 crore
• Overview: Established API and generics player with global operations.
• Focus: Oncology, cardiology, anti-infectives.

18. Emcure Pharmaceuticals

• Revenue: Estimated ₹6,000 crore
• Overview: Major exporter of branded generics and injectables.
• Innovation: Biotech and women’s health.

19. Natco Pharma

• Revenue: Estimated ₹3,000–4,000 crore
• Overview: Specialist in oncology and niche high-value generics.
• Strength: U.S. approvals and local leadership.

20. Laurus Labs

• Revenue: ₹5,300 crore
• Overview: Key API and formulation exporter; rising in nutraceuticals.
• Growth: Expanding into biotechnology.

Industry Overview

India’s pharmaceutical industry contributes significantly to global generics and ranks 3rd by volume and 13th by value. The country’s pharma sector is expected to grow to $130 billion by 2030, driven by exports, biosimilars, and domestic demand.

Conclusion

India’s pharmaceutical landscape is dynamic, diverse, and globally competitive. From top-ranking companies like Sun Pharma, Dr. Reddy’s, and Cipla, to rising stars like Steris Healthcare Pvt Ltd, these organizations are not just contributing to India’s GDP but also improving global health outcomes.

Whether you’re an investor, healthcare professional, or industry analyst, these companies represent the core of India’s pharmaceutical growth story